Cancer reports最新文献

{"title":"Glomus Tumor in the Left Submandibular Region: A Rare Case Report and Literature Review","authors":"Huan Liu,&nbsp;Chengyao Zhu","doi":"10.1002/cnr2.70113","DOIUrl":"10.1002/cnr2.70113","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glomus tumors are rare, benign mesenchymal neoplasms predominantly located in subungual regions of the extremities. Their occurrence in the mandibular region is exceptionally uncommon, presenting unique diagnostic challenges. Only a limited number of submandibular glomus tumors have been documented, leaving their presentation and management largely underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We presented a case of glomus tumor in the submandibular area of a 60-year-old female, which appeared as a purplish-red lesion. In the absence of characteristic symptoms such as tenderness and cold sensitivity, the lesion was initially misdiagnosed as a pigmented nevus. Histopathological analysis subsequently confirmed the diagnosis as a glomus tumor. Immunohistochemical (IHC) staining further confirmed the tumor's smooth muscle and mesenchymal origins, with positive for Vimentin, SMA, Syn, Actin, Desmin, and CD34. The patient underwent surgical tumor excision with no recurrence after 28 months of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case underscores the importance of considering glomus tumors in atypical locations and highlights the need for a comprehensive diagnostic approach to prevent misdiagnosis. Surgical excision remains the primary treatment, with extended postoperative surveillance recommended to monitor for recurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO","authors":"Razieh Heidari,&nbsp;Vahideh Assadollahi,&nbsp;Seyedeh Negar Marashi,&nbsp;Fatemeh Elahian,&nbsp;Seyed Abbas Mirzaei","doi":"10.1002/cnr2.70098","DOIUrl":"10.1002/cnr2.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bioinformatics analysis of hepatocellular carcinoma (HCC) expression profiles can aid in understanding its molecular mechanisms and identifying new targets for diagnosis and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In this study, we analyzed expression profile datasets and miRNA expression profiles related to HCC from the GEO using R software to detect differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>Common DEGs were identified, and a PPI network was constructed using the STRING database and Cytoscape software to identify hub genes. The reduced levels of tumor suppressor miRNAs or down regulated DEmiRs may be increased levels of oncogenes, the oncomirs or up regulated DEmiRs may be decreased levels of tumor suppressor genes in cancerous cells. According to this strategy, increased and decreased DEGs, also increased and decreased DEmiRs were selected. The multimir package was employed to predict target genes for DEmiRs then DEmiRs-hub gene network created. We identified approximately 1000 overlapping DEGs and 60 DEmiRs. Hub genes included RRM2, <i>MELK</i>, <i>KIF11</i>, <i>KIF23</i>, <i>NCAPG</i>, <i>DLGAP5</i>, <i>BUB1B</i>, <i>AURKB</i>, <i>CCNB1</i>, <i>KIF20A</i>, <i>CCNA2</i>, <i>TTK</i>, <i>PBK</i>, <i>TOP2A</i>, <i>CDK1</i>, <i>MAD2L1</i>, <i>BIRC5</i>, <i>ASPM</i>, <i>CDCA8</i>, and <i>CENPF</i>, all associated with significantly worse survival in HCC. miR-224, miR-24, miR-182, miRNA-1-3p, miR-30a, miR-27a, and miR-214 were identified as important DEmiRs with targeting more than six hub genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Generally, our findings offer insight into the interaction of hub genes and miRNAs in the development of HCC by bioinformatics analysis, information that may prove useful in identifying biomarkers and therapeutic targets in HCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARP-1 Inhibition Increases Oxidative Stress in Ets-1-Expressing MDA-MB-231 Breast Cancer Cells","authors":"Magalie Hervieu,&nbsp;Arnaud J. Legrand,&nbsp;Emilie Floquet,&nbsp;Thierry Idziorek,&nbsp;Corentin Spriet,&nbsp;Didier Monté,&nbsp;Vincent Villeret,&nbsp;Marc Aumercier,&nbsp;Souhaila Choul-li","doi":"10.1002/cnr2.70119","DOIUrl":"10.1002/cnr2.70119","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Ets-1 transcription factor plays a primordial role in regulating the expression of numerous genes implicated in cancer progression. In a previous study, we revealed that poly(ADP-ribose) polymerase-1 (PARP-1) inhibition by PJ-34 results in Ets-1 level increase in cells, which is related with cell death of Ets-1-expressing cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The mechanism of the antitumor effect of PARP-1 inhibition was investigated in the Ets-1-expressing MDA-MB-231 breast cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We tested the effects of four PARP inhibitors (PARPi) (PJ-34, Veliparib, Olaparib, and Rucaparib). We first demonstrated that PARPi reduced cells growth through G2/M cell cycle arrest. Next, we evaluated PARP-1 inhibition effect on oxidative DNA damage in Ets-1-overexpressing and Ets-1-non-expressing breast cancer cells and we showed that PARPi led only Ets-1-overexpressing cells to accumulate it, which triggers the DNA damage response as revealed by the increase in the level of a panel of DNA damage-related proteins. Importantly, we demonstrated that PARPi increased reactive oxygen species (ROS), only in Ets-1-overexpressing cells and this is accompanied by upregulation of p47^phox expression, a subunit of the NAPDH oxidase (NOX).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These preliminary findings correlate PARPi-induced oxidative DNA damage/oxidative stress to Ets-1 expression in breast cancer cells.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapse of Diffuse Large B-Cell Lymphoma as Painless Masses in the Abdominal Wall Muscles: A Rare Case Report","authors":"Somar Mansour,&nbsp;Seif-Aldin Abdul Rahman,&nbsp;Majd Mansour,&nbsp;Ali Afif,&nbsp;Raghad Hasan,&nbsp;Nader Abdullah,&nbsp;Zuheir Alshehabi","doi":"10.1002/cnr2.70114","DOIUrl":"10.1002/cnr2.70114","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The most frequent type of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL). Although lymph nodes are the most commonly affected organs compromising 70% of DLBCLs, only 5% of extranodal lymphomas represent skeletal muscle involvement. Specifically, abdominal wall muscle involvement is rare and there are only a few reported cases of DLBCL with this type of muscle involvement. Painful abdominal mass was the main presenting symptom in these reported cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We are reporting a relapsed DLBCL with abdominal wall muscle involvement in a 65-year-old male, presenting with a discomfort and heaviness sensation in the right iliac region with no associated pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A rare case of DLBCL with recurrence in the abdominal wall muscles as painless masses was reported in this case report. To our knowledge, it is considered the fourth reported in the medical literature. It shows the importance of the diagnostic process that combines imaging with histological examination and immune stains for accurate diagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutation Analysis of ASXL1 in Normal Karyotype Myelodysplastic Syndromes: Experience From Pakistan","authors":"Sumera Shaikh,&nbsp;Nida Anwar,&nbsp;Saba Shahid,&nbsp;Shamim Mushtaq,&nbsp;Naveena Fatima,&nbsp;Saima Siddiqui,&nbsp;Qammar Jammal","doi":"10.1002/cnr2.70078","DOIUrl":"https://doi.org/10.1002/cnr2.70078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The challenges in advancing treatment modalities for myelodysplastic syndromes (MDS) may stem from an incomplete understanding of the disease's complex pathophysiology and lack of reliable prognostic molecular markers. Advanced genomic techniques have revolutionized disease prognosis and risk stratification, particularly for cases with a normal karyotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study aimed to analyze ASXL1 mutations in MDS exhibiting a normal karyotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The study enrolled 41 MDS patients with normal karyotypes. Genomic DNA was extracted from peripheral blood samples, followed by Sanger sequencing. The Chi-square and Mann–Whitney <i>U</i> tests were applied to assess the association of age and hemogram with the occurrence of mutations. Survival analysis was done via the Kaplan–Meier method. Statistical operations were performed employing the IBM SPSS Statistics version 24. The patients had a median age of 40 years comprising 28 (68.3%) males and 13 (31.7%) females. ASXL1 mutations were identified in 8 (19.5%), particularly stopgain single nucleotide variant (SNV) and frameshift insertion. The median total leucocyte count × 10⁹/L and blast percentage among the patients with ASXL1 mutation were 3.9 and 4.5, respectively. A survival of 85 weeks was recorded for ASXL1-mutated and nonmutated cases. The association of ASXL1 mutation status with age and studied hematological parameters was found nonsignificant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ASXL1 mutation plays a pivotal role in MDS prognosis, warranting assessment at diagnosis for risk stratification and treatment decisions. Early identification of ASXL1 mutation, particularly in low-risk patients or those with normal karyotype, is imminent to identify patients exhibiting unfavorable prognosis. Integrating molecular insights into existing risk assessment holds significance for improved clinical outcomes, reduction in disease progression, and ultimately the improved quality of life and should be identified early in the course of disease even in the developing world.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in Germany","authors":"Lukas Püllen,&nbsp;Max Naumann,&nbsp;Ulrich Krafft,&nbsp;Felix Püllen,&nbsp;Osama Mahmoud,&nbsp;Mulham Al-Nader,&nbsp;Christopher Darr,&nbsp;Hendrik Borgmann,&nbsp;Christoph Briel,&nbsp;Boris Hadaschik,&nbsp;Johannes Salem,&nbsp;Timur Kuru","doi":"10.1002/cnr2.70092","DOIUrl":"10.1002/cnr2.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite constant improvements, incontinence is one of the most relevant and quality-of-life-reducing side effects of radical prostatectomy (RP) and, in addition to patient-specific factors such as age, the experience of the surgeon/center and the surgical technique used play an important role.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To present current real-world data on short-term incontinence after RP from one of the largest German rehabilitation centers in 2022 and to compare it to the results from the same institution in 2016.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Retrospective, unicentric, univariate analysis of data from 1394 men after RP in 2022 on admission and discharge from the rehabilitation clinic. Incontinence defined as ≥ 1 pad/day was evaluated by quantitative measuring all day incontinence under a defined graduation and compared to the results of 2016. Totally, 1393 men were available for analysis in 2022 compared to 1390 in 2016. Median age for both cohorts was 66 years with minor differences in preoperative PSA levels. Despite different surgical approaches, no significant change in short-term incontinence rates in 2016 and 2022 were noted at discharge (76.9% vs. 77.9%, <i>p</i> = 0.56). A notable increase in patients with ISUP grade Group 2 and a shift towards robotic surgery were observed in 2022 (45.5%–71%). While nerve sparing led to a significant improvement in continence (<i>p</i> &lt; 0.01), lymphadenectomy and T-stage were not related to any significant increase in short-term incontinence rates. Comparing age groups within the cohort, patients &gt; 69 years exhibited the highest risk of short-term incontinence and least likelihood of regaining continence during rehabilitation (<i>p</i> &lt; 0.01). Men treated at a certified prostate cancer center had significantly (<i>p</i> &lt; 0.01) lower short-term incontinence rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study shows little improvement in short-term postoperative incontinence rates after RP in Germany in the last 6 years and known risk factors for postoperative incontinence like age, nerve-sparing surgery, and level of experience were reproduced in our analyses. We conclude not only to carefully select but also to counsel patients before being treated for prostate cancer and to strongly advice treatment at certified centers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report","authors":"Yuto Hibino,&nbsp;Rika Sakai,&nbsp;Hiroyuki Takahashi,&nbsp;Takaaki Takeda,&nbsp;Natsuki Hirose,&nbsp;Mayumi Tokunaga,&nbsp;Kota Washimi,&nbsp;Tomoyuki Yokose,&nbsp;Rika Kasajima,&nbsp;Yukihiko Hiroshima,&nbsp;Yohei Miyagi,&nbsp;Hideaki Nakajima","doi":"10.1002/cnr2.70093","DOIUrl":"10.1002/cnr2.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Erdheim–Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. <i>BRAF</i> and <i>KRAS</i> mutations, which are driver mutations of oncogenes, participate in the same signaling pathway (MAPK/ERK pathway) and are usually mutually exclusive. We report a case of ECD with concurrent <i>BRAF</i>^V600E and <i>KRAS</i>^G12R mutations treated using BRAF and MEK inhibitors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 70-year-old man was referred to our hospital with a mesenteric nodal lesion on computed tomography scan. The patient experienced symptoms consistent with ECD, including central diabetes insipidus. Biopsy revealed histiocytes positive for CD68 and CD163, negative for S100, CD1a, and CD21. Liquid-based comprehensive genomic profiling and tissue-based cancer gene panel test identified <i>BRAF</i>^V600E and <i>KRAS</i>^G12R mutations with different variant allele fraction. Additional immunohistochemistry with an antibody specific to mutant <i>BRAF</i>^V600E protein stained some proliferating histiocytes, consistent with ECD. Based on the genomic profiling results, we hypothesized that there was a coexistence of a clone harboring <i>BRAF</i>^V600E and another clone harboring <i>KRAS</i>^G12R, and planned a combination therapy with BRAF and MEK inhibitors targeting each clone, respectively. The patient received oral encorafenib at 100 mg once daily and oral binimetinib at 15 mg twice daily. The combination therapy resulted in rapid resolution of symptoms and significant improvement in imaging findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case represents a unique presentation of ECD with concurrent <i>BRAF</i>^V600E and <i>KRAS</i>^G12R mutations. Combination therapy with encorafenib and binimetinib targeting each clone resulted in a remarkable therapeutic effect and was well-tolerated. This is the first reported case of ECD treated with encorafenib and binimetinib. The combination therapy with BRAF and MEK inhibitors is one of the rational treatment options for cases of ECD with a suspicion of multiple clones.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Meta-Analysis on the Association of lncRNAs MALAT1, HOTAIR, and AFAP1-AS1 With the Risk of Developing Lymph Node Metastasis in Lung Cancer","authors":"Anha Tasnim,&nbsp;Afra Anjum Sumaiya,&nbsp;Abdullah Al Noman,&nbsp;Anika Tahsin,&nbsp;Abdullah Al Saba,&nbsp;Rubaiat Ahmed,&nbsp;Tahirah Yasmin,&nbsp;A. H. M. Nurun Nabi","doi":"10.1002/cnr2.70091","DOIUrl":"10.1002/cnr2.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Numerous studies have demonstrated the significance of long noncoding RNA (lncRNA) in the development of cancer metastasis. The expression levels of many lncRNAs are elevated in metastatic lung cancer patients compared to non-metastatic lung cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The primary objective of the study was to investigate the association between the expression levels of three lncRNAs (MALAT1, HOTAIR, and AFAP1-AS1) and lymph node metastasis (LNM) of lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cell Press, PubMed, SpringerLink, Web of Science, and Google Scholar were explored to perform the literature search. After screening 1862 articles, 66 English-language articles were selected based on the inclusion and exclusion criteria. From those articles, 17 publications comprising 1622 lung cancer patients were chosen for statistical analyses as well as quality assessment tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forest plot analysis revealed that there was a significant difference in the incidence of LNM between the high and low MALAT1 expression groups (OR = 3.21, 95% CI: 1.34–7.67; random effects model). Significant differences were also observed in the incidence of LNM between patients with high and low HOTAIR expression levels (OR = 4.17, 95% CI: 1.47–11.82; random effects model). The expression level of AFAP1-AS1 was found to be significantly associated with LNM in lung cancer (OR = 2.31, 95% CI: 1.39–3.85, random effects model). Additional analysis from GEPIA and GEO databases revealed that the expression levels of these lncRNAs vary according to the type of tumor tissue, organ of metastasis, and cancer stage. However, these databases show that the result for AFAP1-AS1 is the most aligned with the meta-analysis's findings. Furthermore, several quality assessment tests showed that the AFAP1-AS1 studies are more reliable compared to the studies of other lncRNAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggested that LNM in lung cancer patients is associated mostly with an elevated AFAP1-AS1 lncRNA level among the pool of three lncRNAs analyzed. Before these results can be implemented in a clinical setting, it is essential to conduct further validation and undertake comprehensive analysis to ensure robustness and reliability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases","authors":"Jan Kosťun,&nbsp;Khaled M. Ismail,&nbsp;Martin Pešta,&nbsp;Robert Slunečko,&nbsp;Petr Stráník,&nbsp;Vendula Smoligová,&nbsp;Jiří Presl","doi":"10.1002/cnr2.70082","DOIUrl":"10.1002/cnr2.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Incidence of Cancer Recorded in the Galapagos Archipelago","authors":"Stefano Nicolas Chisesi,&nbsp;Massimo Rugge,&nbsp;Giulia Raffaella Galli,&nbsp;Martina Manni,&nbsp;Veronica Mishell Luzuriaga Delgado,&nbsp;Teodoro Chisesi,&nbsp;Juan Carlos Ruiz,&nbsp;Rina Mariuxi Quinto Briones,&nbsp;Luisa Siculella,&nbsp;Stefano Guzzinati,&nbsp;Manuel Zorzi,&nbsp;Massimo Federico,&nbsp;Anna Iannone","doi":"10.1002/cnr2.70028","DOIUrl":"10.1002/cnr2.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer incidence in the Galapagos archipelago is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In 2021, a task force including Ecuadorian and Italian researchers was established to estimate cancer incidence among the 25 244 Galapagos residents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Registration covered all malignancies, including malignant melanoma and non-melanoma skin cancers; case recording was based on the International Classification of Diseases for Oncology. The data collection involved an active search across all relevant health institutions on the islands and the mainland. Mortality data were obtained from the Ecuador national mortality registry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From January 2013 and December 2019, 174 new cancer cases were recorded, including 134 malignancies (M:F = 58:76) and 40 non-melanoma skin cancers. The mean age at diagnosis was 48 years for males and 56 years for females. Prostate, gastric, and melanocytic malignancies were most incident among males; breast, thyroid, and cervical cancers prevailed in females. The age-standardized incidence rates (ASR) were 80.39 for males and 99.24 for females with a mortality-to-incidence ratio 0.43. These ASRs were significantly lower than those reported in continental Ecuador and other South American countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This pilot cancer registration initiative in the Galapagos record a low incidence of malignancies and requires validation with temporal expansion of cancer registration. The environmental etiology of some of the most common cancers warrants strategic primary and secondary prevention efforts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}